AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe
On Sunday, AstraZeneca Plc (NYSE: AZN ) reported positive late-stage data for investigational therapy efzimfotase alfa in children with hypophosphatasia (HPP), while separately securing European Union approval for cancer drug Enhertu in a broad group of HER2-positive solid tumors, marking two significant milestones acr